Sepsis and bloodstream infections remain a leading cause of death in immunocompromised patients with cancer. The management of these serious infections consist of empiric use of antimicrobial agents which are often overused. Procalcitonin and proadrenomedullin are biomarkers that have been extensively evaluated in the general populations but with little emphasis in the population immunocompromised patients with cancer, where they may have promising roles in the management of febrile patients. In this review, we summarize the available evidence of the potential role of these available biomarkers in guiding antimicrobial therapy to optimize the use of resources in the general patient population. Special emphasis is given to the role of these 2 biomarkers in the immunocompromised and critically ill patients with cancer, highlighting the distinctive utility of each.
Despite major advances in medicine, infections remain a major cause of disease and death in patients with cancer worldwide. Although prompt initiation of appropriate antimicrobial therapy in patients with sepsis has become the standard of care [1, 2] , there is an increasing need to limit the excessive unnecessary use of antimicrobial therapy in the of the rapid emergence of multidrug-resistant organisms with an unmatching development of new antimicrobial agents [3] . Several clinical tools, such as severity scores, have been used to guide clinical decision making. In the past decade, however, there has been a resurging interest in studying the role of various biomarkers in diagnosing and risk-stratifying infectious syndromes and in evaluating antimicrobial prescribing practices.
Although many studies have evaluated the performance of these markers in the general population as well as in critically ill patients, only a few have included patients with cancer and immunocompromised patients. These patients frequently have complicated infections, such as sepsis and bloodstream infections, whereby the clinical manifestations of the infection could be masked and remain occult.
The use of such markers might be useful in identifying those who need antimicrobial therapy and guiding antimicrobial duration in this vulnerable population.
In this review, we focus on 2 biomarkers: procalcitonin (PCT) and proadrenomedullin (pro-ADM) and discuss their role as diagnostic, prognostic, and theragnostic markers particularly in the febrile cancer immunocompromised population. To this end, we conducted a PubMed search for Englishlanguage articles between 1990 and January 2018. Given that PCT was extensively studied as a prognostic and diagnostic marker, we relied on meta-analyses and systematic reviews as well as recent studies (since 2015) pertaining to these fields in our article. In addition, we searched for articles containing the terms PCT, sepsis, and cancer as well as PCT and stewardship. We also searched for pro-ADM and sepsis. For PCT studies, we focused our search on its role in critically ill patients and antimicrobial stewardship. In this review, we use the term compromised to describe patients with cancer who have neutropenia, hematologic cancer (including stem cell transplant recipients), or critical illness.
DIAGNOSTIC ROLE OF PCT AND PRO-ADM
PCT and pro-ADM are 2 biomarkers that have been extensively studied as diagnostic, prognostic, and theragnostic markers in the general population. Numerous published studies have evaluated the diagnostic role of PCT for sepsis, with different results and cutoffs used leading to the conduction of several meta-analyses. PCT seems to be more sensitive and more specific than C-reactive protein (CRP) in diagnosing bacterial infection. This was illustrated in a meta-analysis of 12 studies showing that PCT was significantly more sensitive (88% vs 75%) and more specific (81% vs 67%) than the CRP biomarker in diagnosing bacterial infections [4] . In another meta-analysis, the PCT had a wide range of sensitivity (42%-100%) and specificity (48%-100%) across the studies reviewed and outperformed CRP [5] .
The different cutoff points could result from differences in the study designs, heterogeneity of study population, type of infections, and clinical contexts (eg, pneumonia, meningitis, and bacteremia), as well as the different outcomes measured in hospitalized patients. Furthermore, the various timing and measurement methods of the biomarkers, the different statistical design and analysis, and the variation in the adherence to the biomarkers algorithm may affect the diagnostic performance of the biomarkers.
PCT was found to be a diagnostic marker for bacterial meningitis [6, 7] , acute pyelonephritis [8] , and spontaneous bacterial peritonitis [9] . It also seems to be a reliable marker of bacteremia in febrile adults, with the best area under the curve (AUC) when compared with erythrocyte sedimentation rate and CRP. At a cutoff of 0.4 ng/mL, it has a 98.8% negative predictive value for bacteremia [10] .
Adrenomedullin is also elevated in sepsis, it is rapidly degraded, and results in a smaller molecule, pro-ADM [11] . Pro-ADM levels are higher in patients with localized bacterial infection and bloodstream infections than in healthy controls [12] .
Multiple randomized controlled trials and meta-analyses demonstrated the particular capacity of PCT to differentiate bacterial from nonbacterial causes of respiratory tract infections. Furthermore, PCT-guided algorithms were found to reduce the use of antibiotics when studied in the emergency, primary care, and critical care settings [13, 14] . Some studies have reported improved diagnostic and prognostic accuracy when combining PCT and pro-ADM testing [15] .
PCT AND PRO-ADM AS PROGNOSTIC MARKERS
Multiple studies have looked at PCT and pro-ADM for sepsis prognostication, alone, in combination or in association with disease severity scores. Both PCT and pro-ADM levels were significantly higher in patients sepsis or severe sepsis than in healthy controls or patients with systemic inflammatory response syndrome (SIRS) without an infection. One study showed that pro-ADM, unlike PCT, was more elevated in severe sepsis than in nonsevere sepsis [12] .
Guignant et al [16] retrospectively evaluated pro-ADM as a predictor of mortality at 28 days in the intensive care unit (ICU). At days 5-7 of septic shock, pro-ADM levels were significantly associated with death (odds ratio, 15.35; 95% confidence interval [CI], 3.16-74.57; P = .001). In another prospective study, pro-ADM was superior to PCT in predicting mortality: Pro-ADM levels were significantly higher at onset of sepsis and at days 3-4 in nonsurvivors than in survivors, whereas PCT levels did not differ between the 2 groups [12] . Another study prospectively evaluated the role of pro-ADM as a 28-day mortality predictor and concluded that elevated pro-ADM on days 1 and 5 is a good predictor of death from sepsis. Table 1 summarizes the performance of pro-ADM as a mortality predictor in critically ill patients with sepsis.
Several studies have looked at pro-ADM as a prognostic marker in community-acquired pneumonia (CAP). In a meta-analysis of prospective cohorts looking at pro-ADM in CAP, increased levels were associated with death and an increased rate of complications. The mean cutoff of pro-ADM for predicting mortality was 1.41 ng/mL (95% CI, .95-1.85); pooled sensitivity and specificity approached 75% for CAPassociated mortality [24] .
PCT EFFECTIVENESS IN GUIDING ANTIMICROBIAL THERAPY
PCT has been widely studied in randomized controlled trials as theragnostic tool for guiding antimicrobial therapy in patients with sepsis and septic shock, particularly those who are critically ill. All of these studies excluded immunocompromised patients.
A Cochrane database review [25] including 12 studies published between 2007 and 2015 of ICU patients looked at the impact of PCT algorithms on sepsis-associated mortality and antimicrobial use. It concluded that the duration of antimicrobial therapy was significantly shorter in the PCT-managed arm. However, there were no statistically significant differences in mortality between that arm and the standard-of-care arm. This reduction in the duration of antimicrobial therapy may have major implications in cost reduction, decrease in adverse events, and complications related to antimicrobial use.
PCT use in antimicrobial stewardship has been explored mainly in 2 settings: sepsis in the ICU and acute respiratory infections. Systematic reviews and 4 large randomized controlled trials (3 adult and 1 pediatric) using PCT for antimicrobial therapy guidance have been conducted and published. Table 2 summarizes the findings published since 2015.
Bloos et al [28] enrolled 1089 adult patients with severe sepsis or septic shock to a nonbinding algorithm using PCT versus the standard of care. With an adherence of 40% to the PCT algorithm, antimicrobial use was reduced in the PCT arm by 4.5%. Absence of PCT guidance showed a higher 28-day mortality in a subset of patients receiving selenite supplementation.
In another study, de Jong et al [30] randomly assigned 1575 critically ill patients to either a nonbinding PCT-based algorithm (with a recommendation to stop antimicrobials once the PCT level is 80% less than its initial value or <0.5 ng/mL) or a standard-of-care protocol. Despite a 44% compliance rate in the PCT arm, PCT guidance achieved a significant reduction in daily antimicrobials used and in overall mortality [29] . In patients with sepsis, the use of PCT guidance significantly reduced antimicrobial exposure and was not associated with increased mortality or adverse outcomes [31] .
Similarly, the use of PCT guidance for initiation of antimicrobials in adults presenting with acute respiratory infections was shown to be safe and associated with lower mortality than standard of care; it was also associated with lower antimicrobial exposure and lower antimicrobial-related adverse effects [32] . A recent meta-analysis of 26 randomized controlled trials with a large aggregate patient population with acute respiratory infections showed a significant reduction in mortality with the use of PCT-guided algorithms and a decrease in antibiotic exposure and adverse effects [33] .
Most of the available studies did not well monitor and address the compliance and adherence to PCT-driven algorithms. More pronounced reductions in antimicrobial use might be observed with more rigorous adherence to PCT algorithms. Further randomized controlled trials are warranted, with special effort to improve adherence and compliance through close monitoring of PCT. PCT levels should be used as an independent end point in a well-thought-out algorithm that considers the clinical context as well as the clinician judgment. Furthermore, the effect of PCT-guided algorithms in medical practice, outside randomized controlled trials, is not yet well documented.
PCT AND PRO-ADM IN PATIENTS WITH CANCER
Patients with cancer, including those with neutropenia, constitute a unique patient population because their baseline inflammatory markers might be elevated and driven by cancer itself or treatment complications, such as mucositis and graft-vs-host disease. In addition, severely immuncompromised patients may have a blunted inflammatory response to noxious stimuli, raising concerns as to the performance of standard inflammatory markers that could be impaired.
Furthermore, most of the studies that used PCT to guide antibiotic therapy were conducted in the general population and excluded immunocompromised patients, probably owing to safety concerns. Therefore, extrapolation of the roles of PCT and pro-ADM to the cancer and immunocompromised patient population might not be applicable and must be further evaluated.
Several studies have shown that baseline PCT is more elevated in patients with cancer than in healthy controls [34] [35] [36] . Among afebrile patients with cancer, those with stage IV cancer exhibit higher serum PCT levels than those with lower-stage caner [34, 35] . In the absence of fever, baseline PCT levels are more elevated in patients with hematologic cancer than in those with solid tumors [35] . PCT is elevated in medullary thyroid cancer, but there are reports suggesting that the synthesis of PCT in septic patients is different than in patients with medullary thyroid carcinoma [37] . PCT is also elevated at baseline in patients with lung cancer [38] . PCT elevations have also been reported in those with hepatocellular carcinoma [39] and gastrointestinal neuroendocrine tumors [40] . The few studies that have included immunocompromised patients with cancer are heterogeneous in terms of type of cancer, comorbid conditions, degree of immunosuppression, and baseline characteristics. Further studies in more homogeneous patient populations are warranted.
PCT IN NONNEUTROPENIC FEBRILE PATIENTS WITH SOLID TUMORS
Studies have shown conflicting results in the use of PCT for differentiating infectious from noninfectious fevers in patients with solid tumors. In febrile patients with urologic cancer, PCT was significantly more elevated in infectious than in noninfectious fever [41] . In another study including nonneutropenic febrile patients with solid tumors, PCT levels were occasionally comparable in patients with localized bacterial infection and those with tumor-related fever, with overlap in the ranges of baseline PCT reported. This makes baseline PCT on its own a less useful tool for differentiating infectious from noninfectious causes in patients with solid tumor presenting with fever [42] . However, follow-up PCT levels on days 4-7 of antimicrobial therapy decreased significantly compared with baseline in patients with infection but remained unchanged in those with tumor-related fevers. PCT kinetics could be used to differentiate infection-related from tumor-related fever.
PCT AND PRO-ADM AS DIAGNOSTIC MARKERS IN COMPROMISED PATIENTS WITH CANCER
We have used the term compromised to refer to neutropenia and fever, hematologic cancer, or critical illness in patients with cancer. In a meta-analysis that included 27 PCT studies in adult and pediatric patients, PCT had better performance than CRP and interleukin 6 in differentiating infectious from noninfectious causes of fever [43] (area under the receiver operating characteristic [ROC] curve, 0.87; 95% CI, .84-.9); It is important to note that this meta-analysis included heterogeneous studies in patients with hematopoietic stem cell transplant, hematologic cancer, or solid tumors, studies looking at different outcomes. These outcomes included sepsis, bacteremia, and clinically as well as microbiologically documented infections, using different cutoffs [43] . One study reported that a PCT cutoff of 0.5 ng/mL had a sensitivity as low as 21% for diagnosing bacteremia and sepsis [44] . Several other studies reported that PCT was a reliable marker for bacteremic episodes in febrile neutropenic patients with hematologic cancer, particularly those due to gram-negative pathogens [45, 46] . The experience with pro-ADM is limited to fewer studies: In a study of febrile patients with hematologic cancer, including neutropenic patients (53%), conducted by our group, pro-ADM was compared with PCT in patients with sepsis, SIRS, or no evidence of SIRS. pro-ADM was found to be more suggestive of sepsis than PCT [47] . Another important distinction provided by pro-ADM compared with PCT is that its levels are significantly more elevated in patients with hematologic cancer with localized infections than in those with no infection [47] . PCT levels were similar for those 2 groups, and PCT hence fails as a biomarker of localized infection without systemic sepsis or bloodstream infection. Despite some advantages in the discriminatory function of pro-ADM compared with PCT in immunocompromised patients with cancer, their receiver operating characteristic curves for discriminating bacterial infections were comparable, reported as 0.601 for pro-ADM and 0.54 for PCT [47] . Similar findings were found when PCT and pro-ADM were studied by our group in critically ill patients with cancer: PCT and pro-ADM had similar AUC values for diagnosing bloodstream infections, superior to that of CRP. They both had excellent negative predictive values (92% for pro-ADM at a cutoff of 1 nmol/mL and 93% for PCT at a cutoff of 0.5 ng/mL) [20] .
In patients with hematopoietic stem cell transplant and respiratory complications, pro-ADM and PCT levels were both higher in patients with bacterial and fungal infections than in those with viral infections [48] . Pro-ADM had the highest AUC for bacterial and fungal pulmonary infections (0.75; CI, .60-.91) [48] . Therefore, both markers combined may have additive roles in assessing the possible causes of respiratory complications in this patient population, and together they further suggest the presence of bacterial or fungal infection rather than a viral process.
PCT AND PRO-ADM AS PROGNOSTIC MARKERS IN COMPROMISED PATIENTS WITH CANCER
As in the general population, serum PCT and pro-ADM levels increase with the severity of sepsis and organ failure. In their study, Debiane et al [20] found that follow-up PCT and pro-ADM levels (days 4-7) were good predictors of 2-month mortality. The AUC values for PCT and pro-ADM predicting mortality were 0.77 (95% CI, .67-.87) and 0.82 (.73-.92), respectively. Although both pro-ADM and PCT were good markers for response to therapy, and their levels significantly decreased with repeated testing in responders, they behaved differently in nonresponders. Pro-ADM was superior to PCT in its ability to predict unfavorable responses. Pro-ADM levels significantly increased in nonresponders at days 4-7, but PCT levels did not significantly change. This unique feature of pro-ADM will help distinguish compromised critically ill patients with cancer who have a progressive nonresponding infection from those with tumor-related fever, because pro-ADM levels increase in nonresponders but remain the same in patients with tumor-related fever.
PCT was also useful when combined with clinical predictive assessment; Rast et al [49] compared the performance of PCT with that of other markers in combination with the Glasgow Prognostic Score in patients presenting to the emergency room with infection, cardiovascular disease, or neurologic symptoms. PCT in combination with this score had the highest AUC for 30-day mortality, 0.74 (95% CI, .68-.80; P < .001).
Similarly, Ahn et al [50] combined PCT use with use of the Multinational Association of Supportive Care in Cancer (MASCC) risk index in patients with low-risk neutropenia presenting with fever. This combination improved the risk stratification of patients and helped reclassify patients initially deemed low risk (based on the MASCC risk score) as high-risk patients. Table 3 summarizes key characteristics of PCT and pro-ADM in patients with cancer.
PCT FOR ANTIMICROBIAL STEWARDSHIP IN PATIENTS WITH CANCER
Antibiotics are often used in patients with cancer who have suspected infection, empirically and for long durations, leading to increased cost, drug-related adverse events, and emergence of resistant organisms, which, in turn, are associated with a high mortality and adverse outcomes. The use of a single of PCT and pro-ADM measurement is limited by the significant overlap in PCT and pro-ADM values in all patients, including those with cancer. However, the kinetics of these markers in patients receiving therapy seem to have diagnostic, prognostic, and theragnostic value [47] .
One randomized controlled trial assessing the use of PCT in guiding antimicrobial therapy in 62 patients with cancer and febrile neutropenia showed no significant reduction in antimicrobial duration, with similar rates of relapsed infection between the PCT-guided group and the standard-of-care group [53] . The PCT Higher levels in sepsis/SIRS than in noninfection; higher levels in BSI than in localized bacterial infections; decreases rapidly in response to adequate therapy in patients with infection; possible role for antimicrobial stewardship Similar levels in sepsis and SIRS; similar levels in localized bacterial infections and in patients without infection; no change in nonresponders [20, 35] , [42] Pro-ADM Levels significantly higher in sepsis/SIRS than in noninfection; good marker for BSI as well as localized bacterial infections; = decreases in response to adequate therapy; increases in response to inadequate antimicrobial therapy Not sufficiently explored as theragnostic marker in patients with cancer [20, 47] Abbreviations: BSI, bloodstream infection; CRP, C-reactive protein. PCT, procalcitonin pro-ADM, proadrenomedullin; SIRS, systemic inflammatory response syndrome.
lack of difference could reflect the fact that the study was highly underpowered. Another study from our center showed that neutropenic febrile or septic patients with cancer whose PCT levels drop after antimicrobial therapy have similar outcomes in terms of relapse of infection and 30-day mortality, irrespective of their antimicrobial therapy duration (5-7 vs >7 days) [54] . These data suggest that PCT could have a role in antimicrobial stewardship among febrile patients with cancer, decreasing the duration of antimicrobial therapy, because such therapy beyond 7 days did not improve outcome.
CONCLUSIONS AND FUTURE STUDIES
PCT and pro-ADM may serve as useful and possibly complementary markers for diagnosis of sepsis and bacterial infections in the management of patients with cancer. However, clinicians should keep in mind that cancer on its own could increase the baseline levels of PCT (and probably pro-ADM).
The current evidence also suggests that both PCT and pro-ADM have theragnostic roles in immunocompromised and critically ill patients. Both biomarkers (pro-ADM more than PCT), when levels are compared with baseline, could be helpful to clinicians in determining response to antimicrobial therapy and hence differentiating an infection from noninfectious fever, such as those related to tumor. However, evidence is limited for the use of PCT and pro-ADM in the antimicrobial stewardship of patients with cancer, specifically those with febrile neutropenia. Large prospective randomized controlled trials of these 2 markers in febrile patients with cancer are therefore warranted. 
